Navigation Links
Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments
Date:8/3/2009

SAN DIEGO, Aug. 3, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the second quarter ended June 30, 2009.

Arena reported a lower net loss allocable to common stockholders in the second quarter of 2009 of $38.0 million, or $0.48 per share, compared to a net loss allocable to common stockholders in the second quarter of 2008 of $65.8 million, or $0.89 per share, and a net loss allocable to common stockholders in the first half of 2009 of $88.6 million, or $1.16 per share, compared to a net loss allocable to common stockholders in the first half of 2008 of $120.8 million, or $1.64 per share.

"We are on track to announce results from the BLOSSOM trial in September, which we expect will be the final piece of lorcaserin's NDA that we plan to submit by the end of this year," stated Jack Lief, Arena's President and Chief Executive Officer. "Based on its emerging efficacy, safety and tolerability profile, lorcaserin has the potential to be an important new treatment option for patients needing to better manage their weight and improve their overall health. Our improved financial position strengthens our ability to obtain marketing approval for lorcaserin and our position in partnership discussions."

As expected, research and development expenses declined significantly to $24.2 million in the second quarter of 2009 from $56.2 million in the second quarter of 2008. Research and development expenses declined to $66.8 million in the first half of 2009 from $103.6 million in the first half of 2008. This decrease primarily resulted from decreased clinical trial costs due to the completion of clinical and preclinical studies as Arena prioritized its spending towards activities that support filing a New Drug Ap
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Arena Pharmaceuticals Announces Public Offering of Common Stock
3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
4. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
7. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
9. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
10. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
11. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/28/2014)... and outer body and organ surfaces in the human ... in the inner ear," said Moritz Gegg. Cilia – ... are precisely positioned on many of these epithelial cells. ... coordinated so precisely that for example mucus can be ... from sensory inner ear hair cells," added Heiko Lickert. ...
(Date:10/27/2014)... discarding microscopic warning signs about your health. , But a ... "going to waste." , Brigham Young University chemist Adam Woolley ... of kidney disease and prostate cancer in a few minutes. ... a tiny tube and see how far it goes. , ... will latch onto disease markers and nothing else. Urine from ...
(Date:10/27/2014)... a new therapy by watching others use it, Surprisingly ... New technology is like an influential colleague -- opinionated ... every five to seven days , CHICAGO --- ... they are persuaded to do so by an influential colleague, ... innovations also have relevance for business, education and research. ...
(Date:10/27/2014)... 27, 2014 Jiwa Law Corporation now ... are involved in motor vehicle accidents. The corporation now ... and rehabilitation expenses up to a maximum of $150,000. ... or chiropractor treatments, medications, home support services, and medical ... huge impact on the way you live your life,” ...
(Date:10/27/2014)... -- For children with broken bones, ibuprofen is ... researchers report. Although both medications are ... injuries, oral morphine carries more risk for negative ... that orally administered morphine and other [narcotic painkillers] ... evidence for the oral administration of morphine in ...
Breaking Medicine News(10 mins):Health News:New insights into the development of ciliopathies 2Health News:Prostate cancer, kidney disease detected in urine samples on the spot 2Health News:Persuading doctors to quickly adopt new treatments 2Health News:Persuading doctors to quickly adopt new treatments 3Health News:Jiwa Law Corporation Now Assists Clients With ICBC Claims for Motor Vehicle Accidents 2Health News:For a Child's Fracture, Use Ibuprofen, Not Morphine: Study 2
... problem often leading to diabetes and cardiovascular disease. Being ... // resistant, but not all overweight or obese people ... insulin resistance, however, it is too difficult to administer ... have come up with a simple way to identify ...
... new study was conducted by the Johns Hopkins Bloomberg School ... 55 and older. Researchers used magnetic resonance imaging// to determine ... changes in the brain correlated with the risk of stroke ... moderate alcohol consumption and a decrease in brain size of ...
... surgery, according to a new study done by researchers ... //results are due to medical or psychosocial factors. ... surgery than men. Most have attributed this to the fact ... and have fewer social supports. In this study, investigators from ...
... drugs that lower cholesterol levels, research shows they remain ... a patient is in the hospital or at a ... Foundation looked at the relationship between when lipid-lowering therapy ... outpatient setting and its long-term use. ,For the ...
... major complication of diabetes, despite the fact most are ... performed among the diabetic population. ,Researchers studied ... of about 900 diabetic patients who had been diagnosed ... for 20 years to assess how these microvascular changes ...
... may improve strength and mobility in patients with osteoarthritis.// ... osteoarthritis who were older than age 50. Patients were divided ... week in a swimming pool, the second exercised in a ... the water and gym programs focused on resistance exercises. ...
Cached Medicine News:
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
(Date:10/30/2014)... -- , La fórmula de leche ... tolerancia a la proteína de leche de vaca  ... leche de la vaca (APLV) es la principal alergia alimentaria ... APLV se trataba eliminando las proteínas lácteas de ... posible adquirir tolerancia oral en un número significativo ...
(Date:10/30/2014)... Oct. 30, 2014  TWi Pharmaceuticals, Inc. today announced ... States Food and Drug Administration (FDA) on its Abbreviated ... 23 mg, the generic equivalent to Eisai Inc.,s Aricept® ... patients. TWi Pharmaceuticals is preparing to launch ... subsidiary, TWi Pharmaceuticals USA , at ...
Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... 28, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced plans ... ) on the clinical development of Nile,s proprietary natriuretic ... disease applications. "We are very pleased to ...
... Feb. 28, 2011 PAREXEL International Corporation (Nasdaq: ... presenting at the Raymond James Investors Conference in Orlando, FL. ... be making a presentation on PAREXEL at 2:50 p.m.  ET ... of this presentation will be available through the "Investors" ...
Cached Medicine Technology:Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 2Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 3PAREXEL International to Present at Raymond James Investors Conference 2
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Oval solid 15 mm wide lower plate. Open upper plate with inside dimensions 11 mm x 8 mm. Serrated handle with locking thumb screw and polished finish....
1 mm smooth 45 degrees angled jaws. Cross action serrated handle with polished finish....
Solid lower plate with outside width 28 mm. Open upper plate. Serrated handle with locking thumb screw and polished finish. Right....
Medicine Products: